Collaborative Arrangements and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2022

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship with Biogen

During the three months ended March 31, 2022 and 2021, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended March 31,
	2022			2021
SPINRAZA royalties (commercial revenue)	$	53.8		$	60.0
R&D revenue		40.1			18.1
Total revenue from our relationship with Biogen	$	93.9		$	78.1
Percentage of total revenue		66	%		70	%